Study #2020-0133
A Phase 1/2 Open-label Study to Investigate the Safety, Efficacy, and Pharmacokinetics of Administration of Subcutaneous Blinatumomab for the Treatment of Adults With Relapsed or Refractory B cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)
MD Anderson Study Status
Enrolling
Treatment Agent
Blinatumomab
Description
The study aims to evaluate the safety, efficacy, and tolerability of subcutaneous (SC) blinatumomab for treatment of Acute Lymphoblastic Leukemia (ALL) and to determine the maximum tolerated dose (MTD), and preliminary recommended phase 2 dose(s) (RP2D) of SC administered blinatumomab.
Information and next steps
Disease:
B Cell Precursor Acute Lymphoblastic Leukemia
Study phase:
I
Physician name:
Elias Jabbour
Department:
Leukemia
For general questions about clinical trials:
1-877-632-6789
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.